Company / Revenue per Share
Editas Medicine, Inc. Revenue per Share History
FY2018-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Revenue per Share
$0.39
FY2025
5-year range
$0.24 / $1.33
FY2021-FY2025
Trend
+62.0%
vs FY2024
Sector context
Sector data unavailable
Latest sector comparison
What the data says
Revenue per Share returned to growth in FY2025 after 2 years of decline, reaching $0.39.
Based on SEC 10-K filings.
0.39 in FY2025 with a 5-year CAGR of -7.8%.
Improved from $0.37 to $0.39 over the past 2 years.
Revenue per Share over time
Growth rates
- 3-Year CAGR
- -33.5%
- 5-Year CAGR
- -7.8%
- 10-Year CAGR
- -
Key checks
Key Insights
- In FY2025, revenue per share increased 62.0% year-over-year.
- Peak revenue per share was recorded in FY2022.
- Lowest revenue per share in the period was in FY2018.
Company context
Key Data Points
- Low Piotroski F-Score: 2/9 (multiple financial health concerns)
- Altman Z-Score -2.48 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Revenue per ShareValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $0.39 | +62.0% |
| FY2024 | $0.24 | -35.0% |
| FY2023 | $0.37 | -72.0% |
| FY2022 | $1.33 | +304.0% |
| FY2021 | $0.33 | -44.1% |
| FY2020 | $0.59 | +108.7% |
| FY2019 | $0.28 | +107.0% |
| FY2018 | $0.14 | - |
As of FY2025 · SEC 10-K · Updated Jun 24, 2026